{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:34:58Z","timestamp":1789670098054,"version":"4.0.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bruton\u2019s tyrosine kinase inhibitors (BTKis) are central to the medical management of chronic lymphocytic leukemia. However, accumulating data suggest an important association with cardiovascular (CV) adverse events (AEs), including arrhythmias, hypertension, and bleeding, in patients with chronic lymphocytic leukemia and other hematological malignancies treated with this therapeutic class. Data from comparative trials with BTKis suggest second-generation agents, for example, acalabrutinib and zanubrutinib, may be associated with fewer CV AEs than first-in-class BTKi ibrutinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed and the proceedings of key hematology congresses were searched for relevant information using broad search terms, including chronic lymphocytic leukemia, BTKi, and toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>When managing patients with chronic lymphocytic leukemia, screening before and during treatment to assess CV risk is suggested to guide decision-making. Due to the increased toxicity with ibrutinib, the second-generation BTKis are now preferred (per the NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines]). For patients with a high CV risk, the decision between second-generation BTKi or a time-limited alternative, like venetoclax plus an anti-CD20 monoclonal antibody, should be made on an individual basis after patient consultation and consideration of the presenting characteristics of chronic lymphocytic leukemia in any given patient. The management of anticoagulant\/antiplatelet medication during BTKi treatment requires specific attention, with coexistent medications being carefully assessed before starting a BTKi to reduce the risk of bleeding. For patients with a new-onset or worsening CV events during BTKi therapy, management may involve temporarily stopping the BTKi or switching to another class of therapy. To ensure the best outcomes, a collaborative care approach is essential, and some patients may need to be referred to a cardiologist\/cardio-oncologist for specialist management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline and ongoing CV risk assessment, careful monitoring, management, and a multidisciplinary team approach are all critical to ensure optimal oncologic and CV outcomes for patients with chronic lymphocytic leukemia receiving BTKis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf237","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:53:40Z","timestamp":1753876420000},"source":"Crossref","is-referenced-by-count":15,"title":["Considerations for the practical management of cardiovascular risk with Bruton\u2019s tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-0154","authenticated-orcid":false,"given":"Daniel","family":"Lenihan","sequence":"first","affiliation":[{"name":"Cardio-Oncology Center of Excellence, Cardiac Rehabilitation, and Heart Failure Clinic, Saint Francis Healthcare System , MO 63703,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Bloom","sequence":"additional","affiliation":[{"name":"Cardio-oncology program, NYU Langone Health , New York, NY 11501,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Copeland-Halperin","sequence":"additional","affiliation":[{"name":"Cardiology, Northwell Health , New York, NY 11040,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Fleming","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Vanderbilt University Medical Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fradley","sequence":"additional","affiliation":[{"name":"Cardio-oncology, Hospital of the University of Pennsylvania , Philadelphia, PA 19104,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal","family":"O\u2019Quinn","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema A","family":"Bhat","sequence":"additional","affiliation":[{"name":"Hematology, The Ohio State University Comprehensive Cancer Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2025110501300667400_oyaf237-B1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"key":"2025110501300667400_oyaf237-B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov"},{"key":"2025110501300667400_oyaf237-B3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11899-024-00726-x","article-title":"Frontline therapy of CLL-changing treatment paradigms","volume":"19","author":"Coombs","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"2025110501300667400_oyaf237-B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-024-01001-1","article-title":"Update on the management of relapsed\/refractory chronic lymphocytic leukemia","volume":"14","author":"Bennett","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025110501300667400_oyaf237-B5","year":"2024"},{"key":"2025110501300667400_oyaf237-B6","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.3390\/jcm11206139","article-title":"Bruton\u2019s tyrosine kinase inhibitors: the next frontier of B-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis","volume":"11","author":"Garg","year":"2022","journal-title":"J Clin Med"},{"key":"2025110501300667400_oyaf237-B7","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"key":"2025110501300667400_oyaf237-B8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"2025110501300667400_oyaf237-B9","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025110501300667400_oyaf237-B10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"2025110501300667400_oyaf237-B11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients","volume":"107","author":"Brown","year":"2022","journal-title":"Haematologica"},{"key":"2025110501300667400_oyaf237-B12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","article-title":"Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025110501300667400_oyaf237-B13"},{"key":"2025110501300667400_oyaf237-B14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jaccao.2023.02.001","article-title":"Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients","volume":"5","author":"Diamond","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2025110501300667400_oyaf237-B15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jha2.638","article-title":"A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States","volume":"4","author":"Mato","year":"2023","journal-title":"E J Haem"},{"key":"2025110501300667400_oyaf237-B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.36401\/JIPO-21-12","article-title":"Acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia: a meta-analysis of randomized controlled trials","volume":"5","author":"Htut","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"2025110501300667400_oyaf237-B17","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025110501300667400_oyaf237-B18","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1182\/bloodadvances.2023011641","article-title":"Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib","volume":"8","author":"Moslehi","year":"2024","journal-title":"Blood Adv"},{"key":"2025110501300667400_oyaf237-B19","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"2025110501300667400_oyaf237-B20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025110501300667400_oyaf237-B21","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"key":"2025110501300667400_oyaf237-B22","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"key":"2025110501300667400_oyaf237-B23","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"2025110501300667400_oyaf237-B24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/bjh.19469","article-title":"Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib","volume":"205","author":"Sharman","year":"2024","journal-title":"Br J Haematol"},{"key":"2025110501300667400_oyaf237-B25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/europace\/eux091","article-title":"Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE)","volume":"19","author":"Lip","year":"2017","journal-title":"Europace"},{"key":"2025110501300667400_oyaf237-B26","doi-asserted-by":"publisher","first-page":"e002015","DOI":"10.1161\/JAHA.115.002015","article-title":"Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"4","author":"Rao","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2025110501300667400_oyaf237-B27","doi-asserted-by":"publisher","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"key":"2025110501300667400_oyaf237-B28","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1038\/s41375-023-01869-1","article-title":"Evaluation of bleeding events in patients receiving acalabrutinib therapy","volume":"37","author":"Kumar","year":"2023","journal-title":"Leukemia"},{"key":"2025110501300667400_oyaf237-B29","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1111\/jth.15367","article-title":"Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC subcommittee on hemostasis and malignancy","volume":"19","author":"Wang","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025110501300667400_oyaf237-B30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025110501300667400_oyaf237-B31","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1182\/blood-2017-09-808808","article-title":"Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans","volume":"131","author":"Busygina","year":"2018","journal-title":"Blood"},{"key":"2025110501300667400_oyaf237-B32","author":"National Library of Medicine"},{"key":"2025110501300667400_oyaf237-B33","doi-asserted-by":"publisher","first-page":"k1453","DOI":"10.1136\/bmj.k1453","article-title":"Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study","volume":"361","author":"Staerk","year":"2018","journal-title":"BMJ"},{"key":"2025110501300667400_oyaf237-B34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ Res"},{"key":"2025110501300667400_oyaf237-B35","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2025110501300667400_oyaf237-B36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40959-021-00125-8","article-title":"Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with ibrutinib","volume":"7","author":"Avalon","year":"2021","journal-title":"Cardiooncology"},{"key":"2025110501300667400_oyaf237-B37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2023-174560","article-title":"Pre-existing cardiovascular disease increases the risk of cardiovascular adverse events during Bruton tyrosine kinase inhibitor therapy","volume":"142","author":"Fernandez Turizo","year":"2023","journal-title":"Blood"},{"key":"2025110501300667400_oyaf237-B38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-137800","article-title":"Evaluation of the incidence and risk factors associated with major cardiovascular events in patients receiving acalabrutinib therapy","volume":"136","author":"Azali","year":"2020","journal-title":"Blood"},{"key":"2025110501300667400_oyaf237-B39","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"2025110501300667400_oyaf237-B40","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society \u00ad(IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2025110501300667400_oyaf237-B41","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood-2023-174750","article-title":"Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of elevate-TN","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"key":"2025110501300667400_oyaf237-B42","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025110501300667400_oyaf237-B43","doi-asserted-by":"publisher","first-page":"e064430a","DOI":"10.1097\/01.HS9.0000967492.06443.0a","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study","volume":"7","author":"Al-Sawaf","year":"2023","journal-title":"Hemasphere"},{"key":"2025110501300667400_oyaf237-B44","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2025110501300667400_oyaf237-B45","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11886-023-01916-4","article-title":"Diagnosis and management of cardiovascular effects of Bruton\u2019s tyrosine kinase inhibitors","volume":"25","author":"Aghel","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"2025110501300667400_oyaf237-B46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"2025110501300667400_oyaf237-B47","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.3324\/haematol.2018.207183","article-title":"Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions","volume":"104","author":"Series","year":"2019","journal-title":"Haematologica"},{"key":"2025110501300667400_oyaf237-B48","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1161\/ATVBAHA.115.306130","article-title":"Ibrutinib inhibits platelet integrin \u03b1IIb\u03b23 outside-in signaling and thrombus stability but not adhesion to collagen","volume":"35","author":"Bye","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025110501300667400_oyaf237-B49","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"Peer Review Committee Members. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2025110501300667400_oyaf237-B50","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"2025110501300667400_oyaf237-B51","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","article-title":"International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL","volume":"6","author":"Awan","year":"2022","journal-title":"Blood Adv"},{"key":"2025110501300667400_oyaf237-B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11936-023-01030-2","article-title":"Moving beyond cardiotoxicity detection to prevention: a pharmacologic review","volume":"26","author":"Dent","year":"2024","journal-title":"Curr Treat Options Cardio Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf237\/63895609\/oyaf237.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf237\/63895609\/oyaf237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf237\/63895609\/oyaf237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:30:12Z","timestamp":1762324212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf237\/8219469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf237","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,30]]},"article-number":"oyaf237"}}